Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftazidime + imipenem
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Combination of ceftazidime (a third-generation cephalosporin antibiotic) and imipenem (a carbapenem antibiotic) used to treat bacterial infections, particularly those caused by extensively drug-resistant Pseudomonas aeruginosa (XDRPA). This combination demonstrates synergistic activity against resistant bacteria with mechanisms such as AmpC overexpression or mutation, decreased OprD porin, and upregulated efflux pumps.
02
Targets
Beyond the preview
Go deeper on ceftazidime + imipenem.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftazidime + imipenem.